SCHEMBL2832189

SCHEMBL2832189

CCCCC1(N(C)C)CCN(CCN(C)c2nccc(OC[C@@H]3Cc4ccccc4N3S(=O)(=O)c3c(C)cc(OC)cc3C)n2)CC1

nearest known ligand 0.33

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
BDKRB1 P46663 1/20 0.32
TSHR P16473 1/20 0.30
CRHBP P24387 1/20 0.30
CRHR2 Q13324 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2832195 0.89 LMNA (0.31) LMNAHTTBDKRB1TSHRCRHBP
SCHEMBL2839331 0.88 TSHR (0.33) LMNABDKRB1TSHRCRHBPCRHR2
SCHEMBL2832187 0.88 AVPR1A (0.30)
SCHEMBL2832185 0.88
SCHEMBL2834645 0.86
SCHEMBL2833635 0.86 TSHR (0.32) LMNABDKRB1TSHRCRHBPCRHR2
SCHEMBL2834638 0.86 HTR7 (0.36) BDKRB1
SCHEMBL2832606 0.85 HTR7 (0.34) BDKRB1
SCHEMBL2832192 0.82 NPY1R (0.30)
SCHEMBL2832190 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS LMNA 3222/4885HTT 1922/4885BDKRB1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.